Full-Time
Product Management Consultant
Posted on 5/16/2026
Zeiss
1,001-5,000 employees
Corporate venture capital for deep-tech startups
No salary listed
Bengaluru, Karnataka, India
In Person
 Product (1) |
|---|
- Bachelor or Master of Optometry.
- 3-5 years’ experience in Ophthalmic or related industry.
- Good English communication skills (speaking, reading, writing, intercultural awareness)
- Superb interpersonal, communication, and collaboration skills.
- Great negotiation, persuasion, and problem-solving skills.
- Exceptional organizational and time management skills.
- Full lifecycle product management of key products, mainly in ophthalmic lenses category.
- Drive the execution of all processes in the product lifecycle, including product and market research, competitor analysis, planning, positioning, requirements and roadmap development, and product launch.
- Translate product strategy into detailed requirements for prototyping and final development by engineering teams.
- Collaborate closely with internal team - production, marketing, sales & training teams in the development, QA, and release of products.
- Create product strategy documents that describe business cases, high-level use cases, technical requirements, revenue, and ROI.
- Responsible for performance of assigned product (revenue and GM%).
- Drive the growth of the category by planning the promotion and required necessary interventions.
- Extensive knowledge of marketing strategies and product strategies is a plus.
ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$65.3M
Headquarters
Oberkochen, Germany
Founded
2001
Simplify's Take
What believers are saying
- Digital pathology adoption accelerating in European markets, validated by Mindpeak's 30,000+ patient diagnoses.
- Tissue-selective surgical technology gaining traction; Surgify Medical's €7M Series A demonstrates market demand.
- AI diagnostic automation expanding beyond cancer to other tissue types, creating complementary imaging opportunities.
What critics are saying
- Roche acquisition risk: 50–70% probability Roche acquires Mindpeak within 12–24 months, diluting ZEISS returns.
- Portfolio concentration: 33% historical exit success rate with only 9 investments creates fund underperformance risk.
- Open-source pathology AI models could commoditize Mindpeak's core technology by 2027, eliminating venture returns.
What makes Zeiss unique
- ZEISS Ventures leverages parent company's optics expertise to co-develop hardware-software solutions with startups.
- Strategic focus on industrial and healthcare applications aligns with ZEISS's core business units and innovation hubs.
- Invests in between, beyond, or disruptive technologies to existing ZEISS business units, not just adjacent markets.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Zeiss who can refer or advise you
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Company News
ZEISS has unveiled new digital, AI and surgical innovations for cataract and refractive workflows at the ASCRS conference. The medical technology company is expanding its US cataract portfolio with new irrigation/aspiration handpieces compatible with the DORC EVA NEXUS surgical system, alongside enhanced IOL calculation capabilities for the ZEISS IOLMaster 700. ZEISS also launched VisioGen commercially in the US, a human-verified AI patient engagement platform for ophthalmology practices. The platform integrates with clinic websites to capture patient demand around the clock, with AI-assisted responses reviewed by ZEISS-trained optometrists before delivery. The company showcased ZEISS Collaborative Care, a cloud-based application enabling secure data sharing between eye care professionals, and previewed ZEISS CLINIC 360, pending FDA clearance. ZEISS is celebrating 100 years of US operations this year.
ZEISS Medical Technology has expanded its ophthalmic workflow portfolio in Canada with new diagnostic, visualisation and therapeutic solutions. The company will showcase the innovations at upcoming Canadian ophthalmology conferences in Ottawa and Montréal. Key additions include ICGA for ZEISS CLARUS 700, offering simultaneous FA and ICG capture for clinical assessment, and ZEISS VISULAS green with selective laser trabeculoplasty for retinal photocoagulation. The company has introduced refraction devices ZEISS VISUREF 600 and ZEISS VISUCORE 500 to streamline diagnostic workflows. ZEISS also launched VISULAS yag, a new-generation therapeutic laser for anterior segment photodisruption within cataract workflows. The ZEISS FORUM subscription package, now available in Canada, offers integrated data management with unlimited device licences and lower upfront costs.
ZEISS Medical Technology has launched Collaborative Care, a browser-based application enabling eye care professionals to share data securely, refer patients and coordinate clinical care. Built on the ZEISS Health Data Platform, the solution addresses fragmented data sharing and inefficient referral processes in ophthalmic care. The application offers flexible deployment as either a standalone cloud solution or an integrated extension of ZEISS FORUM. Key features include secure exchange of images and reports, streamlined referral workflows with tracking capabilities, and tools for building professional networks between optometrists and ophthalmologists. ZEISS Collaborative Care was demonstrated at industry events in London and Orlando in February and March 2026. The company generated €2,228 million in revenue in fiscal year 2024/25 with 5,784 employees worldwide.
Custom Surgical, a German ophthalmology company, has raised €3.5 million to advance its platform. The funding will support development of AI-powered features including automated image optimisation and assisted triage processes that help determine case urgency and specialist assignment. The company is already developing its first AI-based triage and screening system. The technology aims to provide initial assessments that guide decisions on how urgently cases need attention and which medical professionals should handle them next.
Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.